
Good morning! Welcome to another edition of Pressure Support, a weekly newsletter simplifying pulmonary and critical care medicine—and the systems that shape it.
This is the TENTH Pressure Support newsletter. We’re chugging along. I’m finding my flow for curating content and analyzing different aspects of the business of pulmonary and critical care medicine.
If you have colleagues who’d benefit from this newsletter, share it with them using the link below:
I’m alpha testing this newsletter—so please let me know your feedback.


Kivo Health Raised $10 Million to Bring Pulmonary Rehab Home. Can It Close the Access Gap?
Read the full article here.


This Michigan study of 4.2 million ED visits found that clinicians who tested more broadly for PE had lower CTPA diagnostic yield (9.6% in the lowest-testing group vs 6.4% in the highest), while 1.4% of acute PEs represented potential missed opportunities linked to lower testing intensity—so the biggest quality lever may be standardizing the initial decision to test rather than simply ordering less imaging. This is a useful, process-focused framework for improving PE care: it targets the earliest decision point and balances overtesting with missed diagnoses, which feels much more actionable for efficient ED and PCCM workflows.
This cross-sectional study of 194 patients with interstitial lung disease found that misdiagnosis was common (70.1%) and diagnosis was delayed in 73.2%, most often after an incorrect diagnosis of tuberculosis or asthma; delays were especially associated with age over 50 and ILD subtype. The big takeaway for me is that we need more reliable, efficient ILD pathways—earlier recognition, better imaging interpretation, and faster multidisciplinary review—to prevent avoidable treatment delays and disease progression.
In this French national cohort of 1,222 lung and heart-lung transplant recipients, days alive and out of the hospital fell from a median of 95% in the year before transplant to 80% in the first year afterward, then recovered to 98.6% in year two; connective tissue disease and single-lung transplant were linked to a tougher first year. This gives patients a much more concrete picture of the early post-transplant burden while also offering reassurance that the disruption is largely temporary. From a PCCM workflow standpoint, I like DAOH because it turns a complicated recovery trajectory into a patient-centered metric that can make pre-transplant counseling more specific and useful.
This single-center prospective cohort followed 150 adults hospitalized during the first COVID-19 wave—101 with ARDS and 49 with pneumonia requiring only nasal-cannula oxygen—at 4 months, 15 months, and 3 years, measuring physical function, frailty, and nine endothelial/inflammatory biomarkers. COVID-19 ARDS survivors had higher GDF-15 and sICAM-1 at discharge and more frailty early on, but most differences converged by 15 months and 3 years; notably, discharge GDF-15 was the only biomarker associated with both ARDS and later frailty. This supports using early post-ICU functional and frailty assessment—rather than assuming persistent endothelial inflammation is the main driver of long-term disability—as a more actionable way to target recovery resources.
A cohort study of 5,269 adults with asthma found that exacerbations began falling sharply after respiratory biologics expanded in 2015, with the biggest gains among patients with the highest baseline burden, although urban and lower-income patients still had higher absolute rates and the study can’t prove biologics alone caused the improvement. This is encouraging population-level evidence that biologics are changing severe asthma care, but the real efficiency win is making access easier and tracking outcomes that matter to patients—control, quality of life, and missed work—not just exacerbations.


PULMONOLOGY
During an incremental CPET, workload continues to rise but V̇O₂ does not plateau.
What is the most accurate terminology for the highest value obtained?

Let me know your feedback!
Keeping it simple,
Jared






